A
Andrew G. Nicholson
Researcher at National Institutes of Health
Publications - 512
Citations - 87875
Andrew G. Nicholson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Idiopathic pulmonary fibrosis. The author has an hindex of 113, co-authored 477 publications receiving 73860 citations. Previous affiliations of Andrew G. Nicholson include National Yang-Ming University & University College London.
Papers
More filters
Journal ArticleDOI
Nonspecific Interstitial Pneumonia: Variable Appearance at High-Resolution Chest CT
Thomas E. Hartman,Stephen J. Swensen,David M. Hansell,Thomas V. Colby,Jeffrey L. Myers,Henry D. Tazelaar,Andrew G. Nicholson,Athol U. Wells,Jay H. Ryu,David E. Midthun,Roland M. du Bois,Nestor L. Müller +11 more
TL;DR: There are a wide variety of CT findings in cases of NSIP, including findings that were nondiagnostic or most compatible with the diagnosis of another chronic infiltrative lung disease.
Journal ArticleDOI
Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias.
Hannah Monaghan,Athol U. Wells,Thomas V. Colby,Roland M. du Bois,David M. Hansell,Andrew G. Nicholson +5 more
TL;DR: Patients with discordant Uip-NSIP results on multiple biopsies show clinical behavior similar to those with concordant UIP-UIP and should be regarded as having CFA/IPF in the correct clinical context, rather than "idiopathic NSIP" for the purposes of management.
Journal ArticleDOI
Inter-observer variation between pathologists in diffuse parenchymal lung disease
Andrew G. Nicholson,Bruce Addis,H Bharucha,Colin Clelland,B Corrin,Allen R. Gibbs,Philip S. Hasleton,Keith M. Kerr,N B N Ibrahim,Susan Stewart,William A Wallace,Andrew Wells +11 more
TL;DR: The results show that the ATS/ERS classification can be applied reproducibly by pathologists who evaluate DPLD routinely, and support the practice of taking multiple biopsy specimens.
Journal ArticleDOI
Rituximab in severe, treatment-refractory interstitial lung disease.
Gregory J. Keir,Toby M. Maher,Damien Ming,Reza Abdullah,Angelo De Lauretis,Melissa Wickremasinghe,Andrew G. Nicholson,David M. Hansell,Athol U. Wells,Elisabetta A. Renzoni +9 more
TL;DR: In patients with severe interstitial lung disease (ILD) progressing despite conventional immunosuppression, rituximab, a B-lymphocyte depleting monoclonal antibody, may offer an effective rescue therapy as discussed by the authors.
Journal ArticleDOI
Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases.
TL;DR: The data suggest that in the majority of cases PCH represents a secondary angioproliferative process caused by postcapillary obstruction rather than a separate disease.